Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA’s therapeutic focus on overcoming primary [...]
Monday, September 9th 2024, 7:01 PM EDT By Renata Stiehl By Linsey Madison Go to Article HORSEHEADS, NY (WENY) -- Senate Majority Leader Chuck Schumer (D-NY) visited Horseheads on Monday to announce the Southern Tier has been selected as the [...]
September 14, 2023 by Brendon Oliver Go to Article Private equity sports investment is on the rise. As leagues have eased ownership rules, dealmakers spy opportunities to gain outsized returns and cultural influence. It's no wonder why: US sports teams' [...]
Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS) SEATTLE, June 29, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune [...]
Adrianna Rodriguez USA TODAY Dr. Joseph Rubelowsky felt as if he had just robbed a bank. Still in his scrubs, he boarded the Falcon 900 jet, sat down and glanced over at the white cooling contraption that held the day’s [...]
SEATTLE, May 24, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company is set to join the Russell Microcap® Index [...]
Surgeon General Dr. Vivek Murthy Urges Action to Ensure Social Media Environments are Healthy and Safe, as Previously-Advised National Youth Mental Health Crisis Continues Today, United States Surgeon General Dr. Vivek Murthy released a new Surgeon General’s Advisory on Social [...]
SEATTLE, April 24, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced [...]
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors: SEATTLE, April 12, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address [...]
Respondology Secures $11 Million Funding Boulder, Colo. — April 13, 2023 —Respondology, a Boulder Heavy Industries portfolio company (BHI) co-founded by digital veterans to eradicate hate, abuse and spam on social media and to empower brands and organizations to optimally [...]
